QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Kamada Stock Price, News & Analysis (NASDAQ:KMDA)

$4.78
+0.02 (+0.42%)
(As of 11/28/2023 ET)
Compare
Today's Range
$4.76
$4.82
50-Day Range
$4.14
$5.38
52-Week Range
$3.72
$5.85
Volume
11,269 shs
Average Volume
30,060 shs
Market Capitalization
$214.46 million
P/E Ratio
36.81
Dividend Yield
N/A
Price Target
$11.00

Kamada MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
129.9% Upside
$11.00 Price Target
Short Interest
Healthy
0.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Kamada in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
107.69%
From $0.13 to $0.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

119th out of 949 stocks

Pharmaceutical Preparations Industry

40th out of 436 stocks


KMDA stock logo

About Kamada Stock (NASDAQ:KMDA)

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Stock Price History

KMDA Stock News Headlines

Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Kamada: Q3 Earnings Snapshot
Here's what Wall Street expects from Kamada's earnings report
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Kamada Q3 2023 Earnings Preview
Kamada Operations Continuing in Israel
Kamada Provides Corporate Update on its Israel Operations
Kamada: Q2 Earnings Snapshot
Kamada earnings preview: what to expect
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/16/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+129.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,320,000.00
Pretax Margin
4.19%

Debt

Sales & Book Value

Annual Sales
$129.34 million
Cash Flow
$0.03 per share
Book Value
$3.93 per share

Miscellaneous

Free Float
28,640,000
Market Cap
$214.46 million
Optionable
Not Optionable
Beta
0.95
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Amir London (Age 54)
    Chief Executive Officer
    Comp: $619k
  • Mr. Chaime Orlev (Age 53)
    Chief Financial Officer
    Comp: $396k
  • Mr. Eran Nir (Age 50)
    Chief Operating Officer
    Comp: $371k
  • Mr. Boris Gorelik (Age 42)
    Vice President of Business Development & Strategic Programs
    Comp: $337k
  • Mr. David Tsur (Age 73)
    Co-Founder & Deputy Chairman of the Board
    Comp: $252k
  • Mr. Nir Livneh B.A. (Age 44)
    L.L.B., VP, General Counsel & Corporate Secretary
  • Ms. Hanni Neheman (Age 53)
    Vice President of Marketing & Sales
  • Ms. Liron Reshef (Age 52)
    Vice President of Human Resources
  • Mr. Jon R. Knight
    Vice President of US Commercial Operations
  • Ms. Shavit Beladev
    Vice President of Kamada Plasma














KMDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings
or view top-rated stocks.

What is Kamada's stock price target for 2024?

1 Wall Street research analysts have issued twelve-month target prices for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price.
View analysts price targets for KMDA
or view top-rated stocks among Wall Street analysts.

How have KMDA shares performed in 2023?

Kamada's stock was trading at $4.01 at the beginning of 2023. Since then, KMDA stock has increased by 19.3% and is now trading at $4.7850.
View the best growth stocks for 2023 here
.

Are investors shorting Kamada?

Kamada saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,100 shares, an increase of 20.5% from the October 31st total of 11,700 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the shares of the stock are short sold.
View Kamada's Short Interest
.

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our KMDA earnings forecast
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to analysts' expectations of $34.18 million. Kamada had a net margin of 4.07% and a trailing twelve-month return on equity of 5.93%. During the same quarter last year, the business earned $0.07 EPS.

What guidance has Kamada issued on next quarter's earnings?

Kamada updated its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $143.83 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.17%), Altshuler Shaham Ltd (0.59%), Meitav Investment House Ltd. (0.17%), Y.D. More Investments Ltd (0.03%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KMDA) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -